peoplePerson
Paul Workman
Drug-discovery pioneer who built the ICR's Cancer Therapeutics Unit and championed the 'pharmacological audit trail'.
Paul Workman led the ICR from 2014 to 2021 and directed its Cancer Research UK Cancer Therapeutics Unit, which discovered or contributed to abiraterone, capivasertib, and HSP90 and PI3K inhibitors.
Role
Harrap Professor of Pharmacology and Therapeutics, ICR; former Chief Executive
Institution
Specialisms
Drug discoveryMolecular pharmacologyKinase and chaperone inhibitors
Profiles
| Title | Journal | Year |
|---|---|---|
| Probing the probes: fitness factors for small molecule tools | Chemistry & Biology | 2010 |
Pages like this
not linked directly; found by shared links- TrialCAPItello-281
Shares Capivasertib, Abiraterone acetate.
- PersonChristopher Lord
Shares Scale up public drug development that takes academic assets to phase 1, The Institute of Cancer Research.
- IdeaAn open map of which cancer proteins any drug can stick to
Shares The Institute of Cancer Research, AI-driven drug & target discovery.
- PersonNicholas James
Shares Abiraterone acetate, The Institute of Cancer Research.
- PersonNicholas Turner
- TrialSTAMPEDE
Shares Abiraterone acetate, The Institute of Cancer Research.
- PersonJohann de Bono
Shares Abiraterone acetate, The Institute of Cancer Research.
- TargetAKT